Kane Biotech Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
WINNIPEG, Manitoba, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced the engagement of Dave D. Hood, President and Chief Executive Officer of DH3 & Associates, as a strategic consultant to help secure non-dilutive funding opportunities through government research or industry grants, foundations, industry partnerships and other avenues. Kane Biotech’s strategy, developed in conjunction with Mr. Hood, will emphasize the pursuit and capture of non-dilutive funding coupled with institutional and strategic investors and will also emphasize identifying new and unique opportunities such as those within defense-related government organizations following the Corporation’s recently-announced extended Cooperative Research and Development Agreement (CRADA) with the U.S. Army.
“Historically, the U.S. federal government is one of the largest investors in medical research and development. These investments are made through a variety of organizations including the Department of Defense (DOD) and the National Institute of Health (NIH), but many times are often overlooked by biotech companies as a potential source of investment. In recent years, the DOD medical community, as well as the NIH, have begun increasing the available funds and effort in later-stage medical device development, products and clinical trials. The goal of these programs have been an increasing shift in improving the commercial success of biotech products, rather than funding only pre-commercial research,” stated Mr. Hood.
“Kane Biotech has a number of strategic clinical and industrial projects which are ideally-positioned for collaboration and support from non-dilutive capital sources. The company’s antimicrobial agents span a broad range of applications that directly impact human health. We aim to strategically capture these funding opportunities to propel high-impact innovation that benefits individuals and industries,” added Mark Ahrens-Townsend, President & CEO of Kane Biotech.
For more than five years, Mr. Hood served as a Senior Advisor for the Principal Assistant for Acquisitions at the U.S. Army Medical Research and Material Command. Mr. Hood has worked with the U.S. Congress and European governments to sponsor funding for innovative products. He holds three patents and has been the stimulus for more than two dozen. He has published and presented extensively on strategies to acquire non-dilutive funding, grants, military research and more across the U.S. and Europe. He is a certified Project Management Professional and has received executive training from the University of South California and the Massachusetts Institute of Technology.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Mark Ahrens-Townsend
President & CEO
Kane Biotech Inc.
+1 (204) 477-7592 ir@kanebiotech.com
Tirth Patel
Vice President - Investor Relations
Edison Advisors
+1 (646) 653-7035 tpatel@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities laws. These statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements in this press release include statements relating to the services to be provided by VLP to the Corporation and the terms and conditions of the written agreement to be entered into between the parties. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including the risk that the services to be provided by VLP will differ from those set out in the agreement to be entered into between the parties and the risk that the parties may not enter into a written agreement. The Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive.
These risks and uncertainties should be considered carefully undue reliance should not be placed on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.
Released August 9, 2018